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Summary
Background:  Curettage  is  a  well-established  treatment  modality  for  giant  cell  tumors  of  bone.
The purpose  of  this  retrospective  study  by  the  French  Sarcoma  and  Bone  Tumor  Study  Groups
(GSF-GETO)  was  to  analyze  various  tumor-speciﬁc  and  surgery-speciﬁc  factors  that  could  inﬂu-
ence the  rate  of  local  recurrence.
Patients  and  method:  Data  was  collected  from  patients  with  giant  cells  tumors  of  the  appendic-
ular skeletal  who  were  treated  by  intralesional  curettage.  The  hazard  ratio  for  tumor  recurrence
was calculated  for  the  different  variables  collected  and  a  multifactorial  analysis  carried  out.
Results: One  hundred  and  ninety-three  surgical  procedures  were  included  from  nine  centers.
One hundred  and  seventy-one  (89%)  were  primary  tumors  and  22  had  been  referred  after  one
or more  recurrences.  The  mean  follow-up  was  6  years  and  11  months.  The  distal  femur  and
proximal tibia  were  the  most  common  locations:  42.5  and  34.2%  of  cases,  respectively.  The
bone defect  after  curettage  was  ﬁlled  in  176  cases  (91.2%)  and  left  empty  in  16  cases.  Local
adjuvant  treatment  (phenol,  alcohol,  cryotherapy  or  combination  treatment)  was  used  in  39
cases (20.2%)  and  systemic  adjuvant  treatment  used  in  24  cases  (calcitonin  11  and  zoledronic
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acid  13).  Local  recurrence  occurred  in  71  cases  (36.8%).  Risk  factors  for  local  recurrence  were
an empty  defect,  a  defect  ﬁlled  with  autograft,  and  patients  treated  before  2005.  Multivariate
analysis showed  that  the  only  risk  factors  for  local  recurrence  were  a  surgical  procedure  before
2005 (odds  ratio  3.6  (95%  CI:  1.2,  7.9)  P  =  0.017)  and  a  bone  defect  ﬁlled  with  autograft  (odds
ratio 3.9  [95%  CI:  1.3,  11.6]  P  =  0.013)
Conclusion:  Neither  tumor-speciﬁc  nor  surgery-speciﬁc  factors  such  as  adjuvant  treatment
were found  to  be  as  risk  factors  for  local  recurrence  after  curettage  of  giant  cell  tumors  in
the appendicular  skeleton.  As  recently  reported,  high-quality  local  curettage  is  probably  the
most effective  technique  to  prevent  local  recurrence.  The  current  study  suggests  that  two  fac-
tors associated  with  more  recent  management  of  these  tumors  in  France,  high-speed  burring
and centralization  to  skilled  surgical  teams,  can  improve  the  quality  of  curettage.
Level of  evidence:  4,  retrospective  cohort  study.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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iant  cell  tumors  in  bone  make  up  5%  of  all  primary  bone
umors.  Their  location,  progression  and  osteolytic  nature
uickly  lead  to  a  disabling  functional  impact,  especially
ince  younger  patients  are  typically  affected.
Intralesional  curettage  is  the  preferred  treatment  to
aintain  function  [1],  but  it  has  a  high  risk  of  local  recur-
ence  (12.5  to  45%)  [2—6].  For  this  reason,  many  local
djuvant  treatments  have  been  used,  including  phenol
2,4,6—8],  alcohol  [4,9]  and  cryotherapy  [6,10—12];  how-
ver,  their  effectiveness  is  debatable.  Similarly,  ﬁlling  of
he  curettage  defect  with  polymethylmetacrylate  cement  is
avored  by  many  surgeons  as  a  way  to  limit  local  recurrence,
ut  this  stated  beneﬁt  is  also  debated  [13].  More  recently,
esults  of  treatment  with  systemic  anti-osteoclastic  agents
ave  been  published  [14]  or  are  being  evaluated  [15—17].
Because  of  the  wide  range  of  practices,  a  study  was  initi-
ted  with  the  GSF-GETO  (French  Sarcoma  Group  and  French
one  Tumor  Study  Group).  The  goal  of  this  study  was  to  eval-
ate  various  tumor-speciﬁc  and  surgery-speciﬁc  factors  and
dentify  which  ones  have  an  effect  on  local  recurrence  after
reatment  by  curettage  of  giant  cell  tumors  of  the  appen-
icular  skeleton.
aterials and patients
his  was  a  retrospective,  multicenter  study  within  GSF-GETO
urgical  teams.  Cases  were  included  if  surgical  treatment
y  curettage  had  been  performed  on  a  giant  cell  tumor  of
one  conﬁrmed  histologically,  either  as  a  primary  treatment
r  upon  recurrence  when  the  patient  had  been  referred
fter  a  single  or  multiple  local  procedures.  This  analysis  only
omprised  the  ﬁrst  procedure  performed  by  the  team;  if  a
ecurrence  was  treated  by  the  same  team,  only  the  ﬁrst
rocedure  was  taken  into  consideration.  Resections  were
xcluded.
Tumors  located  in  the  axial  skeleton  (spine,  sacrum,
elvis)  were  excluded.  The  primary  outcome  was  the  occur-
ence  of  a  recurrence  conﬁrmed  by  histology.  The  follow-up
as  calculated  relative  to  the  surgical  procedure  at  inclu-
ion  on  the  primary  tumor  or  on  the  recurrence  if  the  patient
ad  been  referred.
n
t
1umor-speciﬁc  variables
he  patient’s  epidemiological  data,  primary  or  recurrent
ature  of  the  tumor  and  location  on  the  appendicular  skele-
on  were  recorded.  Tumor  locations  with  less  than  10  cases
ere  grouped  together  for  the  statistical  analysis.  The  size
f  the  tumor  was  recorded  relative  to  the  width  of  the  bone
n  an  A/P  X-ray  view  (±  0.5  bone  width  at  the  level  of  the
argest  diameter).
urgery-speciﬁc  variables
he  participating  center  where  the  patient  had  been  treated
nd  the  surgeon’s  experience  (Junior,  Senior)  were  noted.
ll  patients  were  treated  by  curettage  (inclusion  crite-
ion).  The  use  of  a local  chemical  adjuvant  treatment  was
etermined  based  on  the  surgery  report.  If  the  defect  left
y  curettage  was  subsequently  ﬁlled,  the  type  of  mate-
ial  was  recorded:  polymethylmetacrylate  (PMMA)  cement,
utograft,  allograft  (chips  or  structural)  or  bone  substi-
ute.  In  some  cases,  multiple  materials  were  used  to  ﬁll
he  defect,  but  an  insufﬁcient  number  of  cases  existed  to
erform  a  statistical  analysis  for  each  grouping.  As  a  con-
equence,  if  cement  was  used,  the  case  was  considered  a
MMA  treatment;  if  an  autograft  or  an  allograft  bone  sub-
titute  was  used,  the  case  was  considered  an  allograft  chip
reatment.  And  ﬁnally,  some  patients  were  treated  with  a
ystemic  adjuvant.
tatistical  analysis
ategorical  and  ordinal  data  were  described  by  the  fre-
uency  of  observations.  The  mean  and  standard  deviation
ere  calculated  for  the  age  and  follow-up  data.  Student’s  t-
est  was  used  to  compare  quantitative  variables  and  the  Chi2
est  used  with  qualitative  variables.  If  a  variable  revealed  a
igniﬁcant  risk  (P  <  0.1),  a  stepwise  multivariate  regression
nalysis  was  performed.  A  0.05  threshold  was  used  for  sig-
iﬁcant  ﬁndings  and  the  odds  ratio  was  calculated.  All  of
he  statistical  tests  were  performed  on  IBM  SPSS  Statistics
9  software.
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Results
Overall  results
One  hundred  ninety-three  GCT  cases  were  included  from  the
nine  surgical  centers;  two  centers  contributed  more  than  20
GCT  cases.  Of  these,  171  (87%)  were  performed  for  a  pri-
mary  tumor  and  22  for  a  recurrence  (Table  1).  Eight  tumors
(0.4%)  had  resulted  in  a  fracture  at  the  time  of  diagnosis.
Two  patients  (1%)  presented  with  a  pulmonary  metastasis  at
the  time  of  their  recurrence,  which  was  treated  surgically.
They  were  still  alive  and  in  full  remission  at  the  time  of  the
review.  No  patient  died  because  of  their  GCT;  six  patients
died  of  intercurrent  causes.
A  local  chemical  treatment  was  used  in  39  proce-
dures  (20.2%):  phenol  17  times,  phenol-alcohol  combination
13  times  and  alcohol  seven  times.  Twenty-four  patients
received  a  systemic  treatment.  Zoledronic  acid  (ZOL),  4  mg
every  3  weeks  for  3  months  was  given  to  13  patients  (6.7%)
after  the  surgical  procedure.  Calcitonin  (CALC)  was  given  to
11  patients.
There  were  71  recurrences  (36%)  that  occurred  at  760
days  ±  773  on  average.  The  recurrence  occurred  at  761
(±  755)  days  for  primary  tumors  and  at  756  (±  993)  days  for
recurrent  tumors  (P  =  0.987).  The  majority  of  recurrences
(59  patients,  83%)  occurred  within  3  years.
The  average  follow-up  after  the  surgical  procedure  was
2,161  days  (±  1452).  The  recurrence  rate  was  not  sig-
niﬁcantly  greater  in  patients  with  more  than  3  years  of
follow-up:  56  recurrences  out  of  143  with  more  than  3  years
follow-up  versus  15  recurrences  out  of  50  with  less  than
3  years  (P  =  0.248).
Risk  as  a  function  of  tumor-speciﬁc  and
surgery-speciﬁc  factors
The  tumor  location,  bone  extension  and  treatment  in  the
primary  or  recurrent  stage  did  not  affect  the  recurrence  risk.
There  was  also  no  effect  of  surgeon  experience  and  using  a
local  treatment  (no  matter  the  type)  on  the  recurrence  risk.
The  factors  that  increased  the  risks  of  local  recur-
rence  are  given  in  Table  2.  Treatment  provided  before  2005
(42%  before  2005  and  16%  after  2005),  not  using  a  bone
defect  ﬁller,  using  an  autograft  to  ﬁll  the  defect,  calcitonin
treatment  and  no  bisphosphonate  treatment  were  factors
signiﬁcantly  related  to  a  risk  of  local  recurrence  in  the
univariate  analysis  (P  <  0.1).  In  the  multivariate  analysis,
treatment  before  2005  and  ﬁlling  the  defect  with  an  auto-
graft  were  identiﬁed  as  risk  factors  for  local  recurrence.
Discussion
The  results  of  this  study  showed  that  no  tumor-related  fac-
tors  increased  the  risk  of  local  recurrence  after  curettage
of  appendicular  skeleton  giant  cell  tumors.  The  only  factor
signiﬁcantly  associated  with  reduced  risk  of  local  recur-
rence  was  more  recent  (2005  and  later)  treatment  of  the
tumor.  Moreover,  using  an  autograft  to  ﬁll  the  defect  was
an  independent  risk  factor  for  local  recurrence  (odds  ratio
3.9).  These  overall  results  are  consistent  with  the  results  of
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arious  curettage-only  series  (with  or  without  defect  ﬁlling)
ublished  before  2005  that  reported  a  local  recurrence  rate
f  30  to  55%  [1,5,18,19].
It  has  been  reported  that  tumors  in  the  distal  radius  and
roximal  femur  have  greater  risk  of  local  recurrence  [4].
lthough  the  same  trend  was  found  in  our  series  for  the  dis-
al  radius,  it  was  not  statistically  related  to  an  increased  risk
f  recurrence,  likely  because  of  the  small  number  of  cases
n  =  15).  There  were  an  insufﬁcient  number  of  GCT  cases
n  the  proximal  femur  to  analyze  this  trend.  Extension  to
oft  tissues  [20]  and  aggressive  appearance  on  X-rays  [21]
ave  also  been  reported  to  be  prognostic  factors.  But  these
arameters  could  not  be  evaluated  in  our  study  because
ome  patient  records  had  incomplete  imaging  of  soft  tissues
nd  our  patients  could  not  be  classiﬁed  because  we  lacked  a
entralized  facility  to  evaluate  the  X-ray  images.  Also,  a  few
ecent  studies  have  found  no  correlation  between  radiolog-
cal  classiﬁcation  and  the  risk  of  recurrence.  We  were  only
ble  to  use  the  relative  width  of  the  lesion  on  X-ray  images
s  a  parameter,  but  this  was  not  related  to  the  recurrence
isk.
Moreover,  we  found  no  differences  in  terms  of  recurrence
isk  as  a  function  of  the  management  of  a primary  tumor  or
 recurrent  one.  As  reported  by  Becker  et  al.  [2]  in  a  series
ith  384  patients,  we  also  did  not  ﬁnd  a  greater  recurrence
isk  in  patients  with  a  primary  or  recurrent  tumor.
The  role  of  local  adjuvant  treatment  on  recurrence  is
 long-standing  controversy.  Many  have  reported  a  notice-
ble  beneﬁt  of  local  adjuvant  treatment:  the  recurrence
isk  of  45—65%  without  adjuvants  was  reduced  to  12—18%
ith  adjuvants  [2,3,22].  However,  this  result  was  taken
rom  a  comparison  of  historical  data  over  a  long  period  of
ime,  without  any  controlled  studies.  Cryotherapy  has  been
eported  to  be  effective  [3,11,12]  but  local  complications
ave  occurred  in  up  to  30%  of  cases.  Since  it  was  used  only
nce  in  our  series,  no  conclusions  can  be  drawn  here.
Chemical  adjuvants  were  used  34  times  (phenol,  alco-
ol,  phenol-alcohol  combination).  No  matter  what  type  of
hemical  adjuvant  was  used  or  if  a  chemical  adjuvant  was
sed  at  all,  the  risk  of  local  recurrence  was  unchanged  in  our
tudy.  But  these  products  have  been  shown  effective  in  some
n  vitro  studies  [4,23]  and  many  groups  have  reported  on  the
eneﬁcial  effects  of  phenol  [3,8,24].  In  addition,  recurrence
ates  below  15%  have  been  reported  by  surgical  teams  using
thanol-based  [9]  or  absolute  alcohol-based  [25]  solutions.
owever,  these  typically  are  studies  with  a  small  number  of
atients  and  no  control  group.  Finally,  our  series  was  consis-
ent  with  the  conclusion  of  a  recent  meta-analysis  that  found
o  beneﬁt  to  local  adjuvant  treatment  when  a meticulous,
otorized  curettage  is  performed  [13].
Although  most  surgical  teams  ﬁlled  the  defect  left  by
urettage  of  giant  cell  tumors,  Prosser  et  al.  [5]  believe
hat  defect  ﬁlling  is  useless;  this  conclusion  was  based  on
 series  of  197  cases  where  neither  adjuvant  nor  defect  ﬁll-
ng  was  performed  and  the  recurrence  rate  was  only  19%.  In
he  current  study,  not  ﬁlling  the  defect  was  associated  with
 signiﬁcantly  increased  risk  of  recurrence  that  could  not
e  conﬁrmed  in  the  multivariate  analysis.  However,  in  most
f  the  cases  where  the  defect  was  not  ﬁlled,  the  patients
ad  been  treated  either  locally  or  systemically  with  cal-
itonin.  Disappointing  results  with  this  treatment  strategy
ave  been  recently  reported  [14],  but  it  was  not  possible  to
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Table  1  Main  descriptive  data  and  information  on  local  tumor  progression.
Overall  series
No.  (%)
Progression  without
local  recurrence  (%)
Progression  with  local
recurrence  (%)
Number  of  patients  193  122  (63.2)  71  (36.8)
Age 34.2  (±  12)
(14—77)
31.9  (±  13)  35.4  (±  11)
Gender F/M  119/74
(61.3/38.7)
76/46  43/28
Location
Distal femur 82  (42.5) 53  (64.6) 29  (35.4)
Proximal tibia 66  (34.2) 41  (62.1) 25  (37.9)
Distal tibia  10  (5.2)  5  (50)  5  (50)
Proximal ﬁbula  3  (1.5)
Distal  ﬁbula  2  (1)
Proximal  humerus  9  (4.7)
Distal  radius 15  (87.8)  7  (46.7)  8  (53.3)
Distal ulna 2  (1)
Other  4  (2)
1st surgery/recurrence  171/22
(88.6/11.4)
107/15  (87.7/12.3)  64/7  (90.1/9.9)
Tumor extension
> ½ bone  width 127  (67.8) 81  (68.6) 46  (51.7)
Junior surgeon  26  (13.5)  17  (65.3)  9  (34.6)
Surgery before  2005 151  (78.2) 87  (57.6) 64  (42.4)
Void ﬁller
None  16  (8.8)  6  (41.2)  10  (58.8)
Cement 94  63  (73.2)  23  (26.8)
Autograft 17  6  (35.3)  11  (64.7)
Allograft (bone  chips/structural)  62  42  (64.6)  23  (35.4)
Biomaterials  4  3  (75)  1  (25)
Local adjuvant  treatment  39  (20.2)  27  (69.2)  12  (30.8)
Systemic bisphosphonate  treatment  13  (6.7)  11  2
Systemic calcitonin  treatment  11  (5.7)  3  8
No.: number of patients; data in (): percentage; F: female; M: male.
Table  2  Factors  signiﬁcantly  related  to  risk  of  local  recurrence  based  on  univariate  (P  <  0.1)  and  multivariate  (P  <  0.05)  analysis.
Number  of
patients
Progression  without
recurrence
Local
recurrence
Univariate
analysis  (P)
Multivariate
analysis
Treatment  before  2005  151  87  64  0.002  OR  =  3.6
P =  0.017
(1.2;  7.9)
Void ﬁlling  material
None  16  6  10  0.026  n/s
Autograft 17  6  11  0.012  OR  =  3.9
P =  0.013
(1.3;  11.6)
Calcitonin treatment 11  3  8  0.011  n/s
Bisphosphonate  treatment 13  11  2  0.098  n/s
OR: odds ratio for local recurrence (conﬁdence interval); n/s: not signiﬁcant.
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evaluate  the  effect  of  leaving  the  defect  empty  based  on
our  data.
Surprisingly,  using  an  autograft  to  ﬁll  the  defect  left
by  curettage  was  associated  with  a  signiﬁcantly  increased
risk  of  local  recurrence  in  our  multivariate  analysis.  To  our
knowledge,  no  surgical  team  has  reported  that  autografts
can  affect  the  recurrence  rate.  We  cannot  explain  this  ﬁnd-
ing,  as  it  did  not  seem  to  be  linked  to  any  speciﬁc  center.
Conversely,  many  studies  have  evaluated  the  role  of  PMMA
or  acrylic  cement.  It  is  currently  the  most  heavily  used  bone
void  ﬁller  and  it  also  was  in  our  series  (50.5%  of  cases).  It
provides  many  beneﬁts.  The  excision  margin  is  increased
by  1—2  mm  because  of  the  dual  effect  of  tissue  necrosis
induced  by  the  heat  released  when  the  cement  polymerizes
[26]  and  the  cell  hypoxia  induced  by  its  cytotoxicity  [27].  But
the  role  of  PMMA  in  preventing  recurrences  remains  contro-
versial.  In  a  multicenter  study  of  394  cases,  use  of  PMMA
cement  reduced  the  risk  of  local  recurrence  from  49%  to
22%  in  peripheral  bone  sites  [2].  A  Scandinavia  study  [28]
also  found  that  the  recurrence  risk  was  reduced  from  56%  to
20%  when  the  defect  is  ﬁlled  with  bone  cement.  Conversely,
Turcotte  et  al.  [6]  found  no  differences  related  to  the  type
of  defect  ﬁlling  material.  A  recent  meta-analysis  [13]  con-
ﬁrmed  the  lack  of  cement  effect  when  extensive  curettage
is  performed  and  a  motorized  burr  is  used.  Our  results  are
consistent  with  these  conclusions.
Although  this  was  a  multicenter,  retrospective,  non-
continuous  study,  the  treatment  of  either  primary  or
recurrent  tumors  before  2005  was  a  statistically  signiﬁcant
predictive  factor  for  the  risk  of  recurrence  (relative  risk  of
3.6  in  comparison  to  patients  treated  in  2005  or  later).  How-
ever,  this  result  should  be  interpreted  with  caution.  We  have
no  information  on  the  numbers  of  resection  versus  curet-
tage  cases  during  these  time  periods;  as  a  consequence,  we
do  not  know  if  the  indications  for  curettage  changed  over
time.  The  shorter  follow-up  period  for  patients  treated  after
2005  might  explain  the  fact  that  fewer  recurrence  were
identiﬁed,  but  we  believe  this  to  be  unlikely.  The  average
follow-up  was  1002  ±  555  days  for  patients  treated  starting
in  2005.  Few  patients  had  a  recurrence  beyond  3  years  (12
of  71).  In  addition,  when  only  patients  with  more  than  24
or  36  months  of  follow-up  are  analyzed,  the  risk  for  patients
treated  before  2005  remains  signiﬁcant.  Finally,  in  the  sub-
population  of  patients  with  more  than  3  years  of  follow-up,
there  was  no  difference  in  recurrence,  which  suggests  that
the  ﬁrst  2  to  3  years  are  the  most  important.  This  is  con-
sistent  with  other  published  studies  that  showed  that  when
recurrences  happen  later  on,  most  occur  before  36  months
[5,6].  We  believe  that  the  year  during  which  the  treatment
was  initiated  had  a  major  inﬂuence  on  the  local  outcome  of
the  GCT  in  this  series.  We  found  a  recurrence  rate  of  16.6%  in
patients  treated  after  2005,  which  is  similar  to  recently  pub-
lished  studies  [2,4,22].  Two  factors  can  explain  this  result:
the  treatment  has  become  centralized  and  more  specialized
in  France;  high-speed  burring  is  used  more  systematically
to  improve  the  quality  of  the  curettage.  Others  have  also
drawn  the  same  conclusion:  the  quality  of  the  curettage  is
the  dominant  factor  relative  to  all  the  previously  reported
factors  and  to  the  use  of  adjuvants  [7,13,18].
Two  types  of  systemic  treatment  were  used  in  the  cur-
rent  study.  Calcitonin  treatment  in  a  25  patient  series  was
not  found  to  prevent  recurrences  using  the  given  dosageal  bones  S317
egimen  [14].  Bisphosphonates  were  only  used  11  times  in
ur  series;  there  was  a  non-signiﬁcant  trend  toward  reducing
ecurrences.  Although  the  treatment  rationale  [29,30]  and
he  initial  clinical  results  [15]  are  encouraging,  our  series
as  not  large  enough  to  make  any  conclusions  about  its  use
nd  effectiveness.
onclusion
ur  series  conﬁrms  that  an  elevated  risk  of  local  recurrence
xists  after  curettage  of  a  giant  cell  tumor  in  the  appendicu-
ar  skeleton.  No  tumor-speciﬁc  factor  was  found  to  inﬂuence
he  risk  of  local  recurrence,  which  would  have  driven  the
eed  to  resect  the  tumor.  Local  adjuvant  treatment  does  not
eem  to  prevent  recurrences.  Good  curettage  using  modern
otorized  burrs  is  the  key  to  the  success  of  this  conservative
reatment  modality.  This  study  also  suggests  that  ﬁlling  the
efect  with  an  autograft  must  be  avoided,  but  this  ﬁnding
ust  be  conﬁrmed  in  other  studies.
isclosure of interest
.  Gouin:  no  direct  conﬂict  of  interest  in  that  work  but  indi-
ect  conﬂict  of  interest  in  the  way  of  providing  drugs  by
 compagny  for  an  academic  clinical  study  on  Giant  cells
umors  of  bone.
cknowledgements
he  authors  wish  to  thank  the  teams  participating  in  this
tudy  and  their  representatives:  P.  Anract  and  B.  Tomeno
Paris  Cochin),  P.  Bonnevialle  (Toulouse),  C.  Delloye  (Brus-
els),  F.  Fiorenza  (Limoges),  G.  Missenard  (Paris,  Arago
ospital),  H.  Nouri  (Tunis),  M.  Ropars  (Rennes),  P.  Rosset
Tours),  F.  Sirveaux  (Nancy).
eferences
[1] Szendroi M. Giant cell tumour of bone. J Bone Joint Surg Br
2004;86-B:5—12.
[2] Arbeitsgemeinschaft K, Becker WT, Dohle J, Bernd L, Braun
A, Cserhati M, et al. Local recurrence of giant cell tumor of
bone after intralesional treatment with and without adjuvant
therapy. J Bone and Joint Surg Am 2008;90-A:1060—7.
[3] Capanna R, Fabbri N, Bettelli G. Curettage of giant cell tumor
of bone. The effect of surgical technique and adjuvants on local
recurrence rate. Chir Organ Mov 1990;75(Suppl. 1):206.
[4] Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S,
Rimondi E, et al. Giant cell tumor of the extremity: a review
of 349 cases from a single institution. Cancer Treat Rev
2010;36:1—7.
[5] Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ.
Does curettage without adjuvant therapy provide low recur-
rence rates in giant cell tumors of bone? Clin Orthop Relat Res
2005;435:211—8.
[6] Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri
BA, et al. Giant cell tumor of long bone: a Canadian Sarcoma
Group study. Clin Orthop Rel Res 2002;397:248—58.
[7] Trieb K, Bitzan P, Lang S, Dominkus M, Kotz R. Recurrence of
curetted and bone-grafted giant cell tumours with and without
adjuvant phenol therapy. Eur J Surg Oncol 2001;27:200—2.
S[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[318  
[8] Su YP, Chen WM, Chen TH. Giant cell tumors of bone: an analysis
of 87 cases. Int Orthop 2004;28:239—43.
[9] Jones KB, DeYoung BR, Morcuende JA, Buckwalter JA. Ethanol
as a local adjuvant for giant cell tumor of bone. Iowa
Orthopaedic Journal 2006;26:69—76.
10] Malawer MM, Bickels J, Meller I, Buch RG, Henshaw RM,
Kollender Y. Cryosurgery in the treatment of giant cell
tumor. A long-term follow-up study. Clin Orthop Relat Res
1999;359:176—88.
11] Marcove RC, Weiss LD, Vaghaiwalla MR, Person R, Huvos AG.
Cryosurgery in the treatment of giant cell tumors of bone. A
report of 52 consecutive cases. Cancer 1978;41:957—69.
12] Meller I, Weinbroum A, Bickels J, Dadia S, Nirkin A, Merimsky O,
et al. Fifteen years of bone tumor cryosurgery: a single-center
experience of 440 procedures and long-term follow-up. Eur J
of Surg Oncol 2008;34:921—7.
13] Algawahmed H, Turcotte R, Farrokhyar F, Ghert M. High-Speed
burring with and without the use of surgical adjuvants in
the intralesional management of giant cell tumor of bone:
a systematic review and meta-analysis. Sarcoma 2010:2010,
http://dx.doi.org/10.1155/2010/586090 [pii: 586090].
14] Nouri H, Meherzi MH, Ouertatani M, Mestiri M, Zehi K, Zouari
M, et al. Use of calcitonin in giant cell tumors of bone. Orthop
Traumatol Surg Res 2011;97:520—6.
15] Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R,
et al. Bisphosphonate treatement of aggressive primary, recur-
rent and metastatic giant cell tumour of bone. BMC Cancer
2010;10:462—70.
16] Thomas S, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY,
et al. Denosumab in patients with giant cell tumour of bone:
an open-label, phase 2 study. Oncol Lancet 2010;11:275—80.
17] Tse LF, Wong KC, Kumta SM, Huang L, Chow TS, Grifﬁth JF. Bis-
phosphonates reduce local recurrence in extremity giant cell
tumor of bone: a case-control study. Bone 2008;42:68—73.
18] Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS.
Treatment of giant cell tumors of long bones with curettage and
bone-grafting. J Bone Joint Surg Am 1999;81-A:811—20.
19] Campanacci M, Boriani N, Boriani S, Sudanese S. Giant cell
tumor of bone. J Bone Joint Surg Am 1987;69-A:105—44.
[F.  Gouin,  V.  Dumaine
20] Larsson JE, Lorentzon R, Boquiest L. Giant cell tumor of bone.
A demographic, clinical and histological study of all cases
recorded in the Swedish cancer registry for the years 1958-
through 1968. J Bone Joint Surg 1975;57A:167—73.
21] Toméno B, Forest M. Tumeurs à cellules géantes. In: Duparc J,
editor. Cahiers d’enseignement de la Sofcot, 38. Paris: Expan-
sion Scientiﬁque Franc¸aise; 1990. p. 31—50.
22] Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A,
Koehler G, et al. Giant cell tumor of bone: treatment and
outcome of 214 cases. J Cancer Res Clin Oncol 2008;134:
969—78.
23] Gorzak Y, Kandel R, Deheshi B, Werier J, Turcotte RE, Ferguson
PC, et al. The efﬁcacity of chemical adjuvants on giant cell
tumour of bone. An in vitro study. J Bone Joint Surg B 2010;92-
Br:1475—84.
24] Durr HR, Maier M, Jansson V, Baur A, Reﬁor HJ. Phenol as an
adjuvant for local control in the treatment of giant cell tumour
of the bone. Eur J Surg Oncol 1999;25:610—8.
25] Oh JH, Yoon PW, Lee SH, Cho HS, Kim WS, Kim HS. Surgical
treatment of giant cell tumour of long bone with anhydrous
alcohol adjuvant. Int Orthop 2006;30:490—4.
26] Nelson DA, Barker ME, Hamlin BH. Thermal effects of
acrylic cementation at bone tumour sites. Int J Hyperthermia
1997;13:287—306.
27] Sanjay BK, Frassica FJ, Frassica DA, Unni KK, McLeod RA, Sim
FH. Treatment of giant cell tumor of the pelvis. J Bone Joint
Surg Am 1993;75-A:1466—75.
28] Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A,
Bauer HC, et al. Cement is recommended in intralesional
surgery of giant cell tumors: a Scandinavian Sarcoma Group
study of 294 patients followed for a median time of 5 years.
Acta Orthop 2008;7:86—93.
29] Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM. Bis-
phosphonates induce apoptosis of stromal tumor cells in giant
cell tumor of bone. Calc Tissue Int 2004;75:71—7.30] Chang SS, Suratwal SJ, Jung KM, Doppelt JD, Zhang HZ,
Blaine TA, et al. Biphosphonates may reduce recurrences in
giant cell tumor by inducing apoptosis. Clin Orthop Rel Res
2004;426:103—9.
